The latest data point for ISRG's EPS Surprise % in Q1'26 stands at 17.92%, reflecting a positive but moderated outperformance relative to analyst expectations following a dip to 11.45% in Q4'25. Meanwhile, the EPS Growth (YoY) for the same period is 18.46%, indicating steady year-over-year earnings expansion despite some quarterly variability. Over the period from Q2'23 to Q1'26, EPS Surprise % has shown an overall upward trend with notable volatility, starting at 6.77% and peaking at 25.57% in Q4'24, before stabilizing around 11-21% in recent quarters, highlighting ISRG's consistent ability to exceed forecasts amid fluctuating market dynamics. EPS Growth (YoY) exhibits a similar pattern of positive momentum, with a high of 84.95% in Q4'23 followed by a decline to lows around 12-24% in 2024-2025, yet maintaining above 18% in Q1'26, underscoring resilient growth driven by operational efficiencies in the medical technology sector.